L. Liang

Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.

Yunpeng Liu, Dong Wang, Jie Wang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

N. Yang, K. Ying, Zhijie Wang, 2021, JAMA oncology.

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

J. Desai, K. Rau, M. Friedlander, 2020, Journal for immunotherapy of cancer.

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors

Yangguang Shi, Zhirong Shen, Xiaopeng Ma, 2023, Biomarker Research.

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Xuefei Wang, Yihong Sun, Tianshu Liu, 2022, BMC Medicine.

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

N. Yang, K. Ying, Zhijie Wang, 2020 .

Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)

Yangguang Shi, Zhirong Shen, Yan Yu, 2022, Cancer Research.

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).

Hong Wang, Jianji Pan, Xiaozhong Chen, 2023, Cancer cell.